Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer.

It is a small molecule inhibitor of multiple tyrosine kinases.

[1] Sitravatinib is being developed by Mirati Therapeutics.

[2] Ongoing phase II trials include a trial for liposarcoma,[3] a combination trial for non-small cell lung cancer,[4] and a combination trial with nivolumab for renal cell carcinoma.

[5] Sitravatinib is being evaluated in ongoing trials in patients with advanced non-small cell lung cancer, including in a combination trial with nivolumab in those who are resistant to checkpoint inhibitor therapy, and certain patients who are naïve to checkpoint inhibitor therapy.